Veloxis CEO considers label expansion and acquisitions to increase growth
Danish-American drug group Veloxis Pharmaceuticals has no research and development department, but, according to CEO Craig Collard, the company has several other opportunities to increase sales now that the main asset has started to yield profit.
After Veloxis for the first time reported an anticipated operating profit this year, CEO Craig Collard has started to consider the long-term growth plans.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
